Ascentage Pharma to present ASCO clinical data and AACR preclinical studies in 2026
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Ascentage Pharma Group International said six abstracts from clinical studies of three key drug candidates were selected for presentation at the 2026 American Society of Clinical Oncology Annual Meeting, and it will also present four preclinical studies in poster format at the American Association for Cancer Research 2026 Annual Meeting. The ASCO presentations include three rapid oral presentations and three poster presentations, while the AACR posters feature Olverembatinib (HQP1351), APG-2449 and APG-5918.
At ASCO, the six abstracts highlight Olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China; Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor. The rapid oral presentations cover Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia, updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia, and Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas.
The poster presentations at ASCO include updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase-deficient tumors, and a phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia, the POLARIS-2 trial in progress.
At AACR, the four poster presentations include studies showing Olverembatinib (HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma, and is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma preclinical models. Additional posters cover FAK inhibition by APG-2449 enhancing the antitumor activity of MAPK pathway blockade in BRAF V600E-mutant tumor models, and APG-5918 synergizing with topoisomerase I inhibitors in preclinical small-cell lung cancer models through epigenetic priming of chemosensitivity.
The company said Olverembatinib, APG-2449, and APG-5918 are currently under investigation and have not been approved by the U.S. FDA. It said Olverembatinib is covered by the China National Reimbursement Drug List and that it is conducting an FDA-cleared global registrational Phase III trial, POLARIS-2, for chronic myeloid leukemia, as well as global registrational Phase III trials for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, POLARIS-1, and succinate dehydrogenase-deficient GIST patients, POLARIS-3.